$CURR “This license agreement gives operational freedom to a leader in the supercritical fluid extraction industry who is committed to pharma-grade standards continuing our powered by Cure licensing strategy,” said Rob Davidson, CEO of CURE Pharmaceutical. “Building on this license, we will collaborate with Vanguard Scientific experts to expand the licensed patent estate to cover the most recent advances in the field.”

CURE has granted Vanguard rights to its portfolio of issued and pending process and composition patents for isolating cannabinoids using an advanced supercritical fluid extraction technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of cannabis extracts into multiple dosage forms, CURE has reserved all rights to applying these methods in oral thin film.

"CURE is a leader in cannabinoid drug delivery innovation, and this license and collaboration agreement will give our customers peace of mind when selecting our extraction solutions," said Matthew Anderson, CEO of Vanguard Scientific. "Working with CURE, we intend to further our traction in the marketplace by jointly pursuing a focused patenting strategy in order to offer its clients a broader range of protected and defensible separation capabilities."